# Waters Corporation

**Source:** https://geo.sig.ai/brands/waters-corporation  
**Vertical:** Healthcare Tech  
**Subcategory:** Analytical Instruments  
**Tier:** Leader  
**Website:** waters-corporation.com  
**Last Updated:** 2026-04-14

## Summary

Waters Corporation (WAT) reported ~$2.97B revenue in FY2024. Premier maker of liquid chromatography instruments and mass spectrometers used in pharmaceutical quality control and research. HQ: Milford, MA.

## Company Overview

Waters Corporation is the global leader in analytical instruments and detection technologies for the life science, pharmaceutical, and materials science industries, best known for its high-performance liquid chromatography (HPLC) systems, ultra-high performance liquid chromatography (UPLC) platforms, and mass spectrometry instruments used in drug discovery, quality control, and regulatory compliance. Founded in 1958 by Jim Waters, the company pioneered the commercialization of HPLC technology that is now the standard method for separating and analyzing chemical mixtures in pharmaceutical manufacturing.

Waters reported approximately $2.97 billion in revenue in FY2024, with instruments (30–40% of revenue) complemented by a large and highly recurring chemistry consumables business (columns, reagents) and service/software. The consumables and services business — customers must continually purchase columns and reagents to run their instruments — creates a durable recurring revenue stream with near-100% retention. Waters' instruments are specified in FDA drug approval filings, creating switching costs as changing instruments requires revalidation.

Waters' competitive position is anchored by the ACQUITY UPLC platform (introduced 2004), which remains the gold standard for pharmaceutical chromatography, and its industry-leading Xevo and Synapt mass spectrometers used for bioanalysis and structural proteomics. The company is well-positioned for biologics growth: monoclonal antibodies, gene therapies, and mRNA drugs require sophisticated analytical characterization that only high-resolution mass spectrometry can provide. Waters navigated a challenging 2023–2024 period as biopharma customers reduced capital spending, but underlying demand for its differentiated analytical platforms remains intact.

## Frequently Asked Questions

### What does Waters Corporation make?
Waters makes high-performance liquid chromatography (HPLC/UPLC) instruments and mass spectrometers used by pharmaceutical companies, biotech, and food testing labs to separate, identify, and quantify chemical compounds — including in drug quality control and discovery.

### Why do pharma companies rely on Waters instruments?
Waters' instruments are specified in FDA regulatory drug filings — once a drug's manufacturing process is approved using Waters equipment, switching instruments requires a costly revalidation. This regulatory lock-in creates near-permanent customer relationships for its installed base.

### What is Waters' ticker?
Waters Corporation trades on the NYSE under the ticker WAT.

### What is UPLC?
UPLC (Ultra-Performance Liquid Chromatography) is Waters' proprietary technology that runs chromatography separations 10x faster and with 3x better resolution than conventional HPLC, introduced with the ACQUITY UPLC system in 2004. It became the pharmaceutical industry standard.

### How are Waters Corporation's instruments used in pharmaceutical drug quality control?
Waters' HPLC/UPLC and mass spectrometry instruments are used to verify drug purity, potency, and impurity profiles at every stage of pharmaceutical manufacturing — from raw material testing through final product release. These quality control tests are required by FDA regulations and are specified in the drug's New Drug Application (NDA) or ANDA (generic drug application). Using Waters instruments for quality control is often specified in the regulatory filing, making switch to alternatives a lengthy revalidation process.

### What is Waters Corporation's mass spectrometry business?
Waters' mass spectrometry instruments (including ACQUITY Xevo TQ-S and SELECT SERIES platforms) identify and quantify compounds based on their molecular mass — used in bioanalytical method development (measuring drug levels in patient blood samples in clinical trials), environmental testing, food safety analysis, and proteomics research. Mass spectrometry is a higher-margin, higher-growth business than HPLC alone and represents an increasing portion of Waters' revenue mix.

### What is Waters' software and data informatics business?
Waters' Empower chromatography data software (CDS) is the industry standard for pharmaceutical chromatography data management — controlling instruments, capturing data, and generating compliant reports required for FDA submissions. The CDS software creates significant lock-in; chromatography data systems must be validated to FDA 21 CFR Part 11 requirements, and revalidating a CDS switch is an expensive, multi-year process. Empower's installed base creates recurring software maintenance revenue and switching costs.

### How does Waters compete with Agilent Technologies?
Waters and Agilent Technologies are the two dominant HPLC instrument vendors globally. Waters differentiates on its proprietary UPLC technology (faster, higher-resolution than conventional HPLC) and Empower software's strong compliance position in pharmaceutical. Agilent has broader mass spectrometry portfolio and stronger environmental/food testing market position. Both companies compete intensely for pharmaceutical laboratory instrument contracts, where initial placement leads to long-term consumable and service revenue.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*